StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
NTSC-R.BK$6.20+0.00%
Fair $6.20+0.0%

NTSC-R.BK

Nutrition SC Public Company Limited

Basic Materials / Specialty ChemicalsThailand

$6.20

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $6.20Fund rank 35/100 · Data gapFallback financials|
SA 59/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $95.5M · quality 71.0/100

Data gap 35/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 64/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

59/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists.
Thesis & Journal · NTSC-R.BKLocal privado en este navegador · Nutrition SC Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$827M

P/E

6.9x

↓

EV/EBITDA

3.4x

↓

ROE

10.7%

↑

Gross Margin

23.8%

↑

Debt/Equity

0.09

↓
52-Week Range$6
$6$7

TradingView lightweight chart

NTSC-R.BK price, volumen y niveles de valoración

Último $6.200Periodo +0.0%
Fair value: $6.200

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2025 · 4 años de histórico normalizado

Revenue CAGR

+3.8%

FCF CAGR

+4.7%

FCF margin

7.9%

FCF / Net income

0.80x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.21B · net income $119.9M · FCF $95.5M

2021-FY → 2025-FY

Gross margin

23.8%+1.1% pts

Operating margin

12.2%-0.2% pts

Net margin

9.9%+0.4% pts

FCF margin

7.9%+0.3% pts
MetricTTM
2025
2024
2023
2021
Income Statement
Revenue$1.21B$1.21B$1.11B$955.6M$1.04B
Net Income$119.9M$119.9M$93.4M$69.6M$98.8M
EBITDA$171.9M$171.9M$137.9M$108.9M$136.8M
EPS0.900.900.700.530.74
Gross Margin23.8%23.8%21.7%22.5%22.7%
Operating Margin12.2%12.2%9.6%8.9%12.3%
Net Margin9.9%9.9%8.4%7.3%9.5%
Balance Sheet
Debt/Equity0.090.090.110.120.20
Current Ratio4.414.41———
Cash Flow
Free Cash Flow$95.5M$95.5M$20.2M$103.9M$79.4M
Returns
ROE10.7%10.7%9.1%7.3%16.1%
Valuation
P/E6.896.89———
EV/EBITDA3.443.44———
P/B0.730.73———
Growth & Yield
Revenue Growth8.2%8.2%16.6%-7.9%—
EPS Growth28.6%28.6%31.5%-28.1%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-15.1%

fácil

EPS terminal req.

$0.55

Spread vs growth

43.7%

5Y implied EPS CAGR

-5.9%

fácil

EPS terminal req.

$0.67

Spread vs growth

34.4%

10Y implied EPS CAGR

1.8%

fácil

EPS terminal req.

$1.07

Spread vs growth

26.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total +0.0%

Total return

+0.0%

Start / end P/E

8.9x → 6.9x

EPS bridge

0.70 → 0.90

Residual

-6.3%

EPS growth+28.6%
Multiple rerating-22.2%
Dividend+0.0%
Residual / FX / buybacks / cross-term-6.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.